UNSPSC 51382704: Sulindac sulfide

This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H17FO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UVA8S2DEY, chemically known as sulindac sulfide, (z)-, but more generally known as sulindac sulfide, which bears US NIH Compound Identifier 91605. European Medicines Agency schedules sulindac sulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10744MIG. Most nations, for tariff purposes, schedule sulindac sulfide under HS 29309085.

Sulindac sulfide bears US NLM identifiers UMLS ID C0075615 and NCI Concept Code C29854. SMILES: CC\1=C(C2CC(CCC2/C1=C\C3CCC(CC3)SC)F)CC(=O)O.

UNSPSC 51382704 Sulindac sulfide is a Commodity code that encompasses individual pharmaceutical products procured by state and local health agencies, but the recent state and local contract opportunities posted under this code bear no clear relation to sulindac sulfide specifically. The three most recent solicitations tracked under this code — a Seminole County, Florida procurement for naloxone and drug deactivation systems, a Texas HHS Request for Information on direct-to-manufacturer prescription programs, and a Minnesota multistate cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products — reflect broader pharmaceutical procurement activity spanning emergency medical supplies, prescription program infrastructure, and multi-source generic drug distribution. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving participating state and local facilities.

Opportunities under this code originate from Florida, Texas, and Minnesota, with the Minnesota MMCAP procurement explicitly serving participating jurisdictions including Oregon. Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the county community health building. The Minnesota Department of Administration's MMCAP RFP S1070000015802, posted January 20, 2026 with a response deadline of March 26, 2026, establishes multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026 with the same date as the response deadline, gathers vendor capabilities on direct-to-manufacturer prescription fulfillment. The code shows inconsistent tagging — the specific sulindac sulfide commodity does not appear explicitly in any of these solicitations, suggesting either sparse recent demand for this particular drug or potential misalignment between the code assignment and the work being procured.